

# Primary prophylaxis with ciprofloxacin improves survival and reduces bacterial infections in patients with cirrhosis and ascites

<b>Submission date</b> 19/01/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 09/02/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 09/05/2019	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Ruben Terg

**Contact details**  
Caseros 2061  
Buenos Aires  
Argentina  
1264

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
01/3045

## Study information

**Scientific Title**

Primary prophylaxis with ciprofloxacin improves survival and reduces bacterial infections in patients with cirrhosis and ascites

**Acronym**

SBP - Spontaneous Bacterial Peritonitis

**Study objectives**

The aim of the present study was to assess the efficacy of long-term administration of ciprofloxacin for primary prophylaxis of Spontaneous Bacterial Peritonitis (SBP) in patients with cirrhosis and low protein concentration in ascitic fluid.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

The protocol was approved by local ethic committees (ethics committee of Hospital Bonorino Udaondo and Hospital Alejandro Posadas) on the 6th March 2000.

**Study design**

Multicentre, randomised, double blind, placebo-controlled study

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Treatment

**Participant information sheet****Health condition(s) or problem(s) studied**

Cirrhotic patients with ascites

**Interventions**

Ciprofloxacin 500 mg a day or placebo, oral, during 12 months for intervention group and the control group.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Ciprofloxacin

**Primary outcome measure**

To assess the efficacy of long-term administration of ciprofloxacin for primary prophylaxis of SBP in patients with cirrhosis and low protein concentration in ascitic fluid.

**Secondary outcome measures**

To assess the efficacy of long-term administration of ciprofloxacin for primary prophylaxis of other infections and mortality.

**Overall study start date**

01/03/2000

**Completion date**

01/12/2005

## Eligibility

**Key inclusion criteria**

Diagnosis of cirrhosis was based in clinical, biochemical, ultrasonographic and histological criteria.

Inclusion criteria were:

1. Aged more than 18 and less than 80 years
2. Total protein in ascitic fluid less than 1.5 g/dl
3. Ability to give written informed consent

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Not Specified

**Target number of participants**

100 patients (50 in ciprofloxacin group and 50 in placebo group)

**Total final enrolment**

100

**Key exclusion criteria**

1. A previous episode of SBP
2. Antibiotics in the previous 30 days
3. Pregnancy
4. Active gastrointestinal bleeding

5. Encephalopathy more than grade two
6. Hepatocarcinoma or other malignancies
7. Allergy to quinolones
8. Serum creatinine more than 3 mg/dl
9. Bacterial infection

**Date of first enrolment**

01/03/2000

**Date of final enrolment**

01/12/2005

## Locations

**Countries of recruitment**

Argentina

**Study participating centre**

Caseros 2061

Buenos Aires

Argentina

1264

## Sponsor information

**Organisation**

The Health Council of Investigation of the Government of Buenos Aires (Argentina)

**Sponsor details**

Medrano 350

Piso 2

Buenos Aires

Argentina

1179

**Sponsor type**

Government

**Website**

[http://www.buenosaires.gov.ar/area/salud/cons\\_investigación](http://www.buenosaires.gov.ar/area/salud/cons_investigación)

## Funder(s)

**Funder type**  
Government

**Funder Name**  
The Health Council of Investigation of the Government of Buenos Aires (Argentina) (ref: 01/3045)

## Results and Publications

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2008	09/05/2019	Yes	No